Chimeric antigen receptor-T (CAR-T) cell therapy represents a major breakthrough in cancer immunotherapy, providing remarkable clinical benefits for ...

Breast cancer is the most diagnosed cancer and the second leading cause of cancer-related mortality among women world-wide. Breast cancer is a heterogeneous ...

A new review from the Icahn School of Medicine at Mount Sinai and the Hospital Clínic de Barcelona provides one of the clearest roadmaps to date for understanding and treating liver cancer, one of the ...

This schematic illustrates stratification of gastrointestinal tract cancers based on their sensitivity to immunotherapy, thereby dictating distinct therapeutic paradigms that guide clinical ...

A comprehensive scientific review outlines the progress, limitations, and future prospects of T cell-based immunotherapies for solid tumors, highlighting both biological and technical barriers. Recent ...

The below is a summary of a story that originally appeared on the Duke Health News website. Immunotherapy has transformed cancer care by helping the immune system recognize and destroy tumors. But new ...

The FDA has accepted Cullinan Therapeutics and Taiho Pharmaceutical’s application for zipalertinib, an oral therapy for advanced non-small cell lung cancer with EGFR exon 20 insertion mutations. The ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, side effects and when it could reach patients.

FDA grants Priority Review for Padcev plus Keytruda in muscle-invasive bladder cancer, showing improved survival and reduced ...

Based on results from TROPION-Breast02 showing Daiichi Sankyo and AstraZeneca’s DATROWAY significantly improved overall survival versus chemotherapy in this patient population If approved, DATROWAY ...